Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. [electronic resource]
Producer: 20110916Description: 353-9 p. digitalISSN:- 1532-1827
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzenesulfonates -- administration & dosage
- Dacarbazine -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Metastasis
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- administration & dosage
- Skin Neoplasms -- drug therapy
- Sorafenib
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.